Insulin icodec
Brand Awiqli
Novo Nordisk's once weekly basal insulin, approved in the US for adults with type 2 diabetes in March 2026 and for children aged 10 and older in October 2026.
Insulin icodec comes from Novo Nordisk and sits in the Hormone pathways class on the board. Route: weekly injection. Use tracked here: Glycemic control in adults and in children aged 10 and older with type 2 diabetes. It stands at Approved on the board, with 1 news move logged; the latest is dated 24 Oct 2026.
- 05ApprovedHere now
- 04FiledApplication submitted to a regulator and under review.
- 03Phase 3Large confirmatory trials meant to support a filing.
- 02Phase 2Does it work at all, and at which dose? Hundreds of patients.
- 01Phase 1First doses in people. Safety, dose range, how the body handles it.
- Company
- Novo Nordisk
- Mechanism
- Long acting basal insulin analog designed for once weekly injection
- Given as
- weekly injection
- Lead use on the board
- Glycemic control in adults and in children aged 10 and older with type 2 diabetes
- Moves logged
- 1latest 9 days ago
Insulin icodec news moves
-
Awiqli pediatric approval brings the first weekly insulin to children with type 2 diabetes
The FDA extended Novo Nordisk's once weekly insulin icodec to patients aged 10 and older with type 2 diabetes. The decision leans on adult trials and an 18 patient dosing study, and Lilly's rival weekly insulin is still adults only.
Other hormone pathways molecules on the board, with their current stage.